- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04708288
아르키메데스 생분해성 담도 및 췌장 스텐트의 안전성 및 임상 성능을 평가하기 위한 전향적, 다중 센터, 단일 암, 시판 후 관찰 연구 (Registry)
Significant experience with biodegradable materials has been reported in the orthopedic literature; in particular; biodegradable stents have been used in the endovascular and urologic epithelium. Stents are typically made from polymeric materials including Polylactic Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG), Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g., lactic acid, which is removed from the body by normal metabolic pathways. In the field of gastroenterology, these stents were first introduced in patients with an esophageal stenosis with encouraging results, although esophageal hyperplasia was a frequently encountered complication.
For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that demonstrated that the stents were safe and well tolerated. These stents provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary at various times after implantation.
In 2010, Petryl was the first to use a biodegradable stent in the human bile duct. A stent was successfully placed using percutaneous transhepatic cholangiograpy in two patients with a postsurgical intrahepatic biliary stricture. Transient cholangitis was the only complication encountered and during the two years of follow-up, the bile duct remained patent.
Later, Mauri et al. presented in 2013 and 2016 results of a 107 patient study on a polydioxanone biodegradable biliary stent. The results have been published in the Journal of the European Society of Radiology. The authors concluded that percutaneous placement of a biodegradable biliary stent is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period.
Prior to this study, the ARCHIMEDES device was assessed in the ARCHIMEDES Investigational study which has completed enrolment with 53 patients included, and the results are not yet published. In this study approximately half the stents were deployed in the bile duct (53%) and half in the pancreatic duct. All 53 patients have either completed, exited, or no longer have the study device. No patient remains in the study with a stent in place during the time of the last patient follow-ups. The study concluded without any device-related SAE. Bilirubin was reduced by 25.6%, which exceeded the >20% clinical success criterion, quality of life score improved from 3.7 to 7.9, procedural success was rated 1.4 (good to excellent), and technical success was achieved in all 53 patients.
Data from the ARCHIMEDES Investigational study was used for CE Mark approval, which was obtained in June 2018.
연구 개요
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: NIta Gondaliya
- 전화번호: +49 1716578285
- 이메일: ngondaliya@q3medical.com
연구 연락처 백업
- 이름: Manfred Guelcher
- 전화번호: +4941716578200
- 이메일: mguelcher@q3medical.com
연구 장소
-
-
-
Düsseldorf, 독일, 40217
- 모병
- Evangelisches Krankenhaus Düsseldorf
-
연락하다:
- Biljana Dimitrijevic, PhD
- 전화번호: +49 (0)211919483 601
- 이메일: Biljana.Dimitrijevic@evk-duesseldorf.de
-
연락하다:
- Carina Friesl
- 이메일: carina.friesl@evk-duesseldorf.de
-
수석 연구원:
- Dr. Thomas Veiser, PhD
-
-
-
-
-
Salamanca, 스페인, 37007
- 모병
- Hospital Universitario de Salamanca
-
연락하다:
- Solorzano Garcia Ignacio
- 전화번호: 55400 +34 679441022
- 이메일: isolorzano.ibsal@saludcastillayleon.es
-
수석 연구원:
- Dr. Alberto Álvarez Delgado, MD, PhD
-
-
-
-
-
Ljubljana, 슬로베니아, 1000
- 모병
- University Medical Center Ljubljana
-
연락하다:
- Karin Pulevic, VS
- 전화번호: +38615228515
- 이메일: karin.pulevic@kclj.si
-
연락하다:
- Dr. Martina Jaklič, MD
- 전화번호: +38615222037
- 이메일: martina.jaklic@kclj.si
-
수석 연구원:
- Dr Samo Plut, MD
-
-
-
-
-
Singapore, 싱가포르, 308433
- 완전한
- Tan Tock Seng Hospital Pte Ltd,
-
-
-
-
-
Afula, 이스라엘, 1834111
- 완전한
- Emek Medical Center
-
-
-
-
-
Forlì, 이탈리아, 47121
- 완전한
- AUSL Romagna Ospedale Morgagni - Pierantoni
-
Pavia, 이탈리아, 27100
- 모집하지 않고 적극적으로
- Gastroenterology and Digestive Endoscopy Unit Fondazione I.R.C.C.S. Policlinico San Matteo
-
Roma, 이탈리아, 00128
- 모집하지 않고 적극적으로
- UCBM - Campus Bio-Medico University
-
-
Milano
-
Rozzano, Milano, 이탈리아, 20089
- 모집하지 않고 적극적으로
- Endoscopy Unit, Humanitas Research Hospital
-
-
-
-
-
Paris, 프랑스, 75015
- 모집하지 않고 적극적으로
- Hôpital Européen Georges-Pompidou HEGP Service d'Hépato-gastro-entérologie et endoscopies digestives
-
-
-
-
-
Helsinki, 핀란드, 00290
- 완전한
- HUS Helsinki University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients that will respect the inlcusion criteria will be enrolled in the study.
설명
Inclusion Criteria:
- Patient eligible for implantation of a pancreatic or billiary stent prior to participate in the study and according to current guidelines
- Patient has provided a signed and dated informed consent (according to the laws and regualtions of the country in which the observational study is conducted)
Exclusion Criteria:
- Age < 18 y
- Inability to understand the purpose of the study or refusal to cooperate
- Not available for routine follow-up visits
- Pregnancy
- Currently participating in a confounding trial before reaching first endpoint.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine practice
Participants receiving commercially available ARCHIMEDES Biodegradable Biliary and Pancreatic as part of standard care. Safety outcomes are collected for post-marketing surveillance |
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine clinical practice |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Primary Safety endpoint
기간: From enrollment to the end of treatment, as per the standard of care.
|
Proportion of subjects experiencing procedure- or device-related complications within 30 days including Post-ERCP pancreatitis, Bleeding, Perforation (biliary/pancreatic/duodenal), Stent misplacement, Stent migration, Biliary occlusion, Cholangitis, Severe pain, All-cause death Within 30 days of the index procedure |
From enrollment to the end of treatment, as per the standard of care.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Secondary endpoints are defined as:
기간: Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
Clinical success: patency rate as defined by the rate of freedom of stent replacements at follow-up time points defined by investigators definition of SOC (standard of care) or until planned bridge surgery (defined as no need of stent replacement). Technical success: Accurate stent deployment across the target stricture as evaluated by fluoroscopy and endoscopy. Procedural success will be quantified (using a dedicated score system, Excellence=1, Good=2, Fair=3, Poor=4) by the endoscopist post procedure using the following components:
|
Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- QM-NI-ABS-034
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .